Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Identical p53 gene mutations in different cancers suggest the need for careful treatment.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Nobiletin-loaded vesicles effectively treat skin cancer by restoring normal miRNA and antioxidant levels.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Baicalin may help treat severe drug-induced skin reactions.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

Inactivating both p53 and Rb genes in mice speeds up aggressive skin cancer development.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Blocking mTORC1 reduces skin tumor growth in mice.